1
|
Vallot D, Brillouet S, Pondard S, Vija L, Texier JS, Dierickx L, Courbon F. Impact of different models based on blood samples and images for bone marrow dosimetry after 177Lu-labeled somatostatin-receptor therapy. EJNMMI Phys 2024; 11:32. [PMID: 38564043 PMCID: PMC10987460 DOI: 10.1186/s40658-024-00615-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 01/15/2024] [Indexed: 04/04/2024] Open
Abstract
BACKGROUND Peptide receptor radionuclide therapy with 177Lu-DOTATATE is a recognized option for treating neuroendocrine tumors and has few toxicities, except for the kidneys and bone marrow. The bone marrow dose is generally derived from a SPECT/CT image-based method with four timepoints or from a blood-based method with up to 9 timepoints, but there is still no reference method. This retrospective single-center study on the same cohort of patients compared the calculated bone marrow dose administered with both methods using mono, bi- or tri-exponential models. For the image-based method, the dose was estimated using Planetdose© software. Pearson correlation coefficients were calculated. We also studied the impact of late timepoints for both methods. RESULTS The bone marrow dose was calculated for 131 treatments with the blood-based method and for 17 with the image-based method. In the former, the median absorbed dose was 15.3, 20.5 and 28.3 mGy/GBq with the mono-, bi- and tri-exponential model, respectively. With the image-based method, the median absorbed dose was 63.9, 41.9 and 60.8 with the mono-, bi- and tri-exponential model, respectively. Blood samples after 24h post-injection did not evidence any change in the absorbed bone marrow dose with the bi-exponential model. On the contrary, the 6-day post-injection timepoint was more informative with the image-based model. CONCLUSION This study confirms that the estimated bone marrow dose is significantly lower with the blood-based method than with the image-based method. The blood-based method with a bi-exponential model proved particularly useful, without the need for blood samples after 24h post-injection. Nevertheless, this blood-based method is based on an assumption that needs to be more validated. The important difference between the two methods does not allow to determine the optimal one to estimate the true absorbed dose and further studies are necessary to compare with biological effects.
Collapse
|
2
|
Arjuna A, Milborne B, Putra AR, Mulyaningsih TR, Setiawan H, Islam MT, Felfel R, Ahmed I. Development of samarium-doped phosphate glass microspheres for internal radiotheranostic applications. Int J Pharm 2024; 653:123919. [PMID: 38373598 DOI: 10.1016/j.ijpharm.2024.123919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/03/2023] [Revised: 01/25/2024] [Accepted: 02/16/2024] [Indexed: 02/21/2024]
Abstract
Internal radiotherapy delivers radioactive sources inside the body, near to or into malignant tumours, which may be particularly effective when malignancies are not responding to external beam radiotherapy. A pure beta emitter, 90Y, is currently used for internal radiotherapy. However, theranostic radionuclide-doped microspheres can be developed by incorporating 153Sm, which emits therapeutic beta and diagnostic gamma energies. This study investigated the production of high concentrations of samarium-content doped phosphate-based glass microspheres. The glass P60 (i.e. 60P2O5-25CaO-15Na2O) was mixed with Sm2O3 at ratios of 75:25 (G75:Sm25), 50:50 (G50:Sm50) and 25:75 (G25:Sm75) and processed via flame spheroidisation. Scanning electron microscopy (SEM) and energy dispersive X-ray (EDX) confirmed the microsphere uniformity with significantly high samarium content up to 44 % in G25:Sm75. Via X-ray diffraction (XRD) analysis, samarium-doped microspheres appeared to be glass-ceramic in nature. Mass-loss, size and pH changes were performed over 28 days, revealing a significant increase in samarium microsphere stability. After 15 min of neutron activation (neutron flux 3.01 × 1013 n.cm-2.s-1), the specific activity of the microspheres (G75:Sm25, G50:Sm50 and G25:Sm75) was 0.28, 0.54 and 0.58 GBq.g-1, respectively. Therefore, the samarium microspheres produced in this study provide great potential for improving internal radiotherapy treatment for liver cancer by avoiding complex procedures and using less microspheres with shorter irradiation time.
Collapse
Affiliation(s)
- Andi Arjuna
- Advanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, UK; Faculty of Pharmacy, Hasanuddin University, Makassar 90245, Indonesia
| | - Ben Milborne
- Advanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, UK
| | - Amal Rezka Putra
- Research Organization for Nuclear Energy (ORTN), National Research and Innovation Agency (BRIN), Tangerang Selatan, Banten 15314, Indonesia
| | - Theresia Rina Mulyaningsih
- Research Organization for Nuclear Energy (ORTN), National Research and Innovation Agency (BRIN), Tangerang Selatan, Banten 15314, Indonesia
| | - Herlan Setiawan
- Research Organization for Nuclear Energy (ORTN), National Research and Innovation Agency (BRIN), Tangerang Selatan, Banten 15314, Indonesia
| | - Md Towhidul Islam
- Advanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, UK
| | - Reda Felfel
- Advanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, UK
| | - Ifty Ahmed
- Advanced Materials Research Group, Faculty of Engineering, University of Nottingham, Nottingham NG7 2RD, UK.
| |
Collapse
|
3
|
Vergnaud L, Badel JN, Giraudet AL, Kryza D, Mognetti T, Baudier T, Rida H, Dieudonné A, Sarrut D. Performance study of a 360° CZT camera for monitoring 177Lu-PSMA treatment. EJNMMI Phys 2023; 10:58. [PMID: 37736779 PMCID: PMC10516832 DOI: 10.1186/s40658-023-00576-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/16/2023] [Accepted: 09/05/2023] [Indexed: 09/23/2023] Open
Abstract
BACKGROUND The aim of this study was to investigate the quantification performance of a 360° CZT camera for 177Lu-based treatment monitoring. METHODS Three phantoms with known 177Lu activity concentrations were acquired: (1) a uniform cylindrical phantom for calibration, (2) a NEMA IEC body phantom for analysis of different-sized spheres to optimise quantification parameters and (3) a phantom containing two large vials simulating organs at risk for tests. Four sets of reconstruction parameters were tested: (1) Scatter, (2) Scatter and Point Spread Function Recovery (PSFR), (3) PSFR only and (4) Penalised likelihood option and Scatter, varying the number of updates (iterations × subsets) with CT-based attenuation correction only. For each, activity concentration (ARC) and contrast recovery coefficients (CRC) were estimated as well as root mean square. Visualisation and quantification parameters were applied to reconstructed patient image data. RESULTS Optimised quantification parameters were determined to be: CT-based attenuation correction, scatter correction, 12 iterations, 8 subsets and no filter. ARC, CRC and RMS results were dependant on the methodology used for calculations. Two different reconstruction parameters were recommended for visualisation and for quantification. 3D whole-body SPECT images were acquired and reconstructed for 177Lu-PSMA patients in 2-3 times faster than the time taken for a conventional gamma camera. CONCLUSION Quantification of whole-body 3D images of patients treated with 177Lu-PSMA is feasible and an optimised set of parameters has been determined. This camera greatly reduces procedure time for whole-body SPECT.
Collapse
Affiliation(s)
- Laure Vergnaud
- Centre de lutte contre le cancer Léon Bérard, Lyon, France.
- CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France.
| | - Jean-Noël Badel
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
- CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France
| | | | - David Kryza
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
- Hospices Civils de Lyon, Université de Lyon, Université Claude Bernard Lyon 1, LAGEPP UMR 5007 CNRS, Lyon, France
| | | | - Thomas Baudier
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
- CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France
| | - Hanan Rida
- Département de médecine nucléaire, Centre Henri Becquerel, Rouen, France
| | - Arnaud Dieudonné
- Département de médecine nucléaire, Centre Henri Becquerel, Rouen, France
| | - David Sarrut
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
- CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France
| |
Collapse
|
4
|
Jiang Y, Wu Q, Hou M, Hai W, Zhang M, Li B, Zhang C. pH-sensitive gold nanoclusters labeling with radiometallic nuclides for diagnosis and treatment of tumor. Mater Today Bio 2023; 19:100578. [PMID: 36880082 PMCID: PMC9984684 DOI: 10.1016/j.mtbio.2023.100578] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/08/2022] [Revised: 02/02/2023] [Accepted: 02/07/2023] [Indexed: 02/11/2023] Open
Abstract
The acidic microenvironment is one of the remarkable features of tumor and is also a reliable target for tumor theranostics. Ultrasmall gold nanoclusters (AuNCs) have good in vivo behaviors, such as non-retention in liver and spleen, renal clearance, and high tumor permeability, and held great potential for developing novel radiopharmaceuticals. Herein, we developed pH-sensitive ultrasmall gold nanoclusters by introducing quaternary ammonium group (TMA) or tertiary amine motifs (C6A) onto glutathione-coated AuNCs (TMA/GSH@AuNCs, C6A-GSH@AuNCs). Density functional theory simulation revealed that radiometal 89Sr, 223Ra, 44Sc, 90Y, 177Lu, 89Zr, 99mTc, 188Re, 106Rh, 64Cu, 68Ga, and 113Sn could stably dope into AuNCs. Both TMA/GSH@AuNCs and C6A-GSH@AuNCs could assemble into large clusters responding to mild acid condition, with C6A-GSH@AuNCs being more effective. To assess their performance for tumor detection and therapy, TMA/GSH@AuNCs and C6A-GSH@AuNCs were labeled with 68Ga, 64Cu, 89Zr and 89Sr, respectively. PET imaging of 4T1 tumor-bearing mice revealed TMA/GSH@AuNCs and C6A-GSH@AuNCs were mainly cleared through kidney, and C6A-GSH@AuNCs accumulated in tumors more efficiently. As a result, 89Sr-labeled C6A-GSH@AuNCs eradicated both the primary tumors and their lung metastases. Therefore, our study suggested that GSH-coated AuNCs held great promise for developing novel radiopharmaceuticals that specifically target the tumor acidic microenvironment for tumor diagnosis and treatments.
Collapse
|
5
|
Vergnaud L, Giraudet AL, Moreau A, Salvadori J, Imperiale A, Baudier T, Badel JN, Sarrut D. Patient-specific dosimetry adapted to variable number of SPECT/CT time-points per cycle for [Formula: see text]Lu-DOTATATE therapy. EJNMMI Phys 2022; 9:37. [PMID: 35575946 PMCID: PMC9110613 DOI: 10.1186/s40658-022-00462-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2021] [Accepted: 04/20/2022] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The number of SPECT/CT time-points is important for accurate patient dose estimation in peptide receptor radionuclide therapy. However, it may be limited by the patient's health and logistical reasons. Here, an image-based dosimetric workflow adapted to the number of SPECT/CT acquisitions available throughout the treatment cycles was proposed, taking into account patient-specific pharmacokinetics and usable in clinic for all organs at risk. METHODS Thirteen patients with neuroendocrine tumors were treated with four injections of 7.4 GBq of [Formula: see text]Lu-DOTATATE. Three SPECT/CT images were acquired during the first cycle (1H, 24H and 96H or 144H post-injection) and a single acquisition (24H) for following cycles. Absorbed doses were estimated for kidneys (LK and RK), liver (L), spleen (S), and three surrogates of bone marrow (L2 to L4, L1 to L5 and T9 to L5) that were compared. 3D dose rate distributions were computed with Monte Carlo simulations. Voxel dose rates were averaged at the organ level. The obtained Time Dose-Rate Curves (TDRC) were fitted with a tri-exponential model and time-integrated. This method modeled patient-specific uptake and clearance phases observed at cycle 1. Obtained fitting parameters were reused for the following cycles, scaled to the measure organ dose rate at 24H. An alternative methodology was proposed when some acquisitions were missing based on population average TDRC (named STP-Inter). Seven other patients with three SPECT/CT acquisitions at cycles 1 and 4 were included to estimate the uncertainty of the proposed methods. RESULTS Absorbed doses (in Gy) per cycle available were: 3.1 ± 1.1 (LK), 3.4 ± 1.5 (RK), 4.5 ± 2.8 (L), 4.6 ± 1.8 (S), 0.3 ± 0.2 (bone marrow). There was a significant difference between bone marrow surrogates (L2 to L4 and L1 to L5, Wilcoxon's test: p value < 0.05), and while depicting very doses, all three surrogates were significantly different than dose in background (p value < 0.01). At cycle 1, if the acquisition at 24H is missing and approximated, medians of percentages of dose difference (PDD) compared to the initial tri-exponential function were inferior to 3.3% for all organs. For cycles with one acquisition, the median errors were smaller with a late time-point. For STP-Inter, medians of PDD were inferior to 7.7% for all volumes, but it was shown to depend on the homogeneity of TDRC. CONCLUSION The proposed workflow allows the estimation of organ doses, including bone marrow, from a variable number of time-points acquisitions for patients treated with [Formula: see text]Lu-DOTATATE.
Collapse
Affiliation(s)
- Laure Vergnaud
- CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
| | | | - Aurélie Moreau
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
| | - Julien Salvadori
- ICANS - Institut de cancérologie Strasbourg Europe, Strasbourg, France
| | - Alessio Imperiale
- ICANS - Institut de cancérologie Strasbourg Europe, Strasbourg, France
| | - Thomas Baudier
- CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
| | | | - David Sarrut
- CREATIS, CNRS UMR 5220, INSERM U 1044, Université de Lyon, INSA-Lyon, Université Lyon 1, Lyon, France
- Centre de lutte contre le cancer Léon Bérard, Lyon, France
| |
Collapse
|
6
|
Frezza A, Joachim-Paquet C, Chauvin M, Després P. Validation of irtGPUMCD, a GPU-based Monte Carlo internal dosimetry framework for radionuclide therapy. Phys Med 2020; 73:95-104. [PMID: 32334403 DOI: 10.1016/j.ejmp.2020.04.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2019] [Revised: 04/07/2020] [Accepted: 04/12/2020] [Indexed: 11/28/2022] Open
Abstract
PURPOSE Monte Carlo (MC) simulations are highly desirable for dose treatment planning and evaluation in radiation oncology. This is true also in emerging nuclear medicine applications such as internal radiotherapy with radionuclides. The purpose of this study is the validation of irtGPUMCD, a GPU-based MC code for dose calculations in internal radiotherapy. METHODS The female and male phantoms of the International Commission on Radiological Protection (ICRP 110) were used as benchmarking geometries for this study focused on 177Lu and including 99mTc and 131I. Dose calculations were also conducted for a real patient. For phantoms, twelve anatomical structures were considered as target/source organs. The S-values were evaluated with irtGPUMCD simulations (108 photons), with gamma branching ratios of ICRP 107 publication. The 177Lu electrons S-values were calculated for source organs only, based on local deposition of dose in irtGPUMCD. The S-value relative difference between irtGPUMCD and IDAC-DOSE were evaluated for all targets/sources considered. A DVHs comparison with GATE was conducted. An exponential track length estimator was introduced in irtGPUMCD to increase computational efficiency. RESULTS The relative S-value differences between irtGPUMCD and IDAC-DOSE were <5% while this comparison with GATE was <1%. The DVHs dosimetric indices comparison between GATE and irtGPUMCD for the patient led to an excellent agreement (<2%). The time required for the simulation of 108 photons was 1.5 min for the female phantom, and one minute for the real patient (<1% uncertainty). These results are promising and let envision the use of irtGPUMCD for internal dosimetry in clinical applications.
Collapse
Affiliation(s)
- Andrea Frezza
- Department of Physics, Engineering Physics and Optics and Cancer Research Center, Université Laval, Quebec City, QC G1V 0A6, Canada
| | - Charles Joachim-Paquet
- Department of Physics, Engineering Physics and Optics and Cancer Research Center, Université Laval, Quebec City, QC G1V 0A6, Canada
| | - Maxime Chauvin
- CRCT, UMR 1037, Inserm, Université Toulouse III Paul Sabatier, Toulouse, France
| | - Philippe Després
- Department of Physics, Engineering Physics and Optics and Cancer Research Center, Université Laval, Quebec City, QC G1V 0A6, Canada; Department of Radiation Oncology and Research Center of CHU de Québec - Université Laval, Quebec City, QC G1R 2J6, Canada.
| |
Collapse
|
7
|
Adashek JJ, Salgia M, Dizman N, Kessler J, Pal SK. Concomitant Radioembolization and Immune Checkpoint Inhibition in Metastatic Renal Cell Carcinoma. Case Rep Oncol 2018; 11:276-280. [PMID: 29867435 PMCID: PMC5981597 DOI: 10.1159/000489995] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2018] [Accepted: 05/09/2018] [Indexed: 12/15/2022] Open
Abstract
This case represents the challenge and creativity necessary when treating patients with metastatic renal cell carcinoma who have been exposed to multiple lines of therapy. At present, treatment with immune checkpoint inhibition has stabilized and improved the metastatic disease of this patient with the exception of hepatic lesions. This isolated progression within the liver led the employment of radioembolization, which successfully treated those metastases. This is the first documented case of metastatic renal cell carcinoma controlled with concurrent use of immune checkpoint inhibition and radioembolization for both extrahepatic and hepatic metastases, respectively. This case can be construed as a potential example of the abscopal effect and may provide the basis for understanding this type of response in select patients.
Collapse
Affiliation(s)
- Jacob J Adashek
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA
| | - Meghan Salgia
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA
| | - Nazli Dizman
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA
| | - Jonathan Kessler
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA
| | - Sumanta K Pal
- Department of Medical Oncology and Experimental Therapeutics, City of Hope Comprehensive Cancer Center, Duarte, California, USA
| |
Collapse
|
8
|
Cikankowitz A, Clavreul A, Tétaud C, Lemaire L, Rousseau A, Lepareur N, Dabli D, Bouchet F, Garcion E, Menei P, Couturier O, Hindré F. Characterization of the distribution, retention, and efficacy of internal radiation of 188Re-lipid nanocapsules in an immunocompromised human glioblastoma model. J Neurooncol 2016; 131:49-58. [PMID: 27783195 DOI: 10.1007/s11060-016-2289-4] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2016] [Accepted: 10/09/2016] [Indexed: 10/20/2022]
Abstract
Internal radiation strategies hold great promise for glioblastoma (GB) therapy. We previously developed a nanovectorized radiotherapy that consists of lipid nanocapsules loaded with a lipophilic complex of Rhenium-188 (LNC188Re-SSS). This approach resulted in an 83 % cure rate in the 9L rat glioma model, showing great promise. The efficacy of LNC188Re-SSS treatment was optimized through the induction of a T-cell immune response in this model, as it is highly immunogenic. However, this is not representative of the human situation where T-cell suppression is usually encountered in GB patients. Thus, in this study, we investigated the efficacy of LNC188Re-SSS in a human GB model implanted in T-cell deficient nude mice. We also analyzed the distribution and tissue retention of LNC188Re-SSS. We observed that intratumoral infusion of LNCs by CED led to their complete distribution throughout the tumor and peritumoral space without leakage into the contralateral hemisphere except when large volumes were used. Seventy percent of the 188Re-SSS activity was present in the tumor region 24 h after LNC188Re-SSS injection and no toxicity was observed in the healthy brain. Double fractionated internal radiotherapy with LNC188Re-SSS triggered survival responses in the immunocompromised human GB model with a cure rate of 50 %, which was not observed with external radiotherapy. In conclusion, LNC188Re-SSS can induce long-term survival in an immunosuppressive environment, highlighting its potential for GB therapy.
Collapse
Affiliation(s)
- Annabelle Cikankowitz
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,AMaROC, ONIRIS, Ecole Nationale Véterinaire de Nantes, Nantes, France.,PRIMEX (Plateforme de Radiobiologie et d'Imagerie Expérimentale), Université d'Angers, Angers, France
| | - Anne Clavreul
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France. .,Service de Neurochirurgie, CHU d'Angers, Angers, France.
| | - Clément Tétaud
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,PRIMEX (Plateforme de Radiobiologie et d'Imagerie Expérimentale), Université d'Angers, Angers, France
| | - Laurent Lemaire
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France
| | - Audrey Rousseau
- Laboratoire de Pathologie Cellulaire et Tissulaire, CHU d'Angers, Angers, France
| | - Nicolas Lepareur
- Centre Régional de Lutte Contre le Cancer (CRLCC) Eugène Marquis, Rennes, France
| | - Djamel Dabli
- Médecine Nucléaire et Biophysique, CHU d'Angers, Angers, France
| | - Francis Bouchet
- Médecine Nucléaire et Biophysique, CHU d'Angers, Angers, France
| | - Emmanuel Garcion
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France
| | - Philippe Menei
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,Service de Neurochirurgie, CHU d'Angers, Angers, France
| | - Olivier Couturier
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,Médecine Nucléaire et Biophysique, CHU d'Angers, Angers, France
| | - François Hindré
- INSERM U1066 MINT (Micro et Nanomédecines Biomimétiques), Université d'Angers, Angers, France.,PRIMEX (Plateforme de Radiobiologie et d'Imagerie Expérimentale), Université d'Angers, Angers, France
| |
Collapse
|
9
|
Qaim SM. Nuclear data for production and medical application of radionuclides: Present status and future needs. Nucl Med Biol 2016; 44:31-49. [PMID: 27821344 DOI: 10.1016/j.nucmedbio.2016.08.016] [Citation(s) in RCA: 107] [Impact Index Per Article: 13.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/28/2016] [Revised: 08/22/2016] [Accepted: 08/23/2016] [Indexed: 11/30/2022]
Abstract
INTRODUCTION The significance of nuclear data in the choice and medical application of a radionuclide is considered: the decay data determine its suitability for organ imaging or internal therapy and the reaction cross section data allow optimisation of its production route. A brief discussion of reaction cross sections and yields is given. STANDARD RADIONUCLIDES The standard SPECT, PET and therapeutic radionuclides are enumerated and their decay and production data are considered. The status of nuclear data is generally good. Some existing discrepancies are outlined. A few promising alternative production routes of 99mTc and 68Ga are discussed. RESEARCH-ORIENTED RADIONUCLIDES The increasing significance of non-standard positron emitters in organ imaging and of low-energy highly-ionizing radiation emitters in internal therapy is discussed, their nuclear data are considered and a brief review of their status is presented. Some other related nuclear data issues are also mentioned. PRODUCTION OF RADIONUCLIDES USING NEWER TECHNOLOGIES The data needs arising from new directions in radionuclide applications (multimode imaging, theranostic approach, radionanoparticles, etc.) are considered. The future needs of data associated with possible utilization of newer irradiation technologies (intermediate energy cyclotron, high-intensity photon accelerator, spallation neutron source, etc.) are outlined. CONCLUSION Except for a few small discrepancies, the available nuclear data are sufficient for routine production and application of radionuclides. Considerable data needs exist for developing novel radionuclides for applications. The developing future technologies for radionuclide production will demand further data-related activities.
Collapse
Affiliation(s)
- Syed M Qaim
- Institut für Neurowissenschaften und Medizin, INM-5 (Nuklearchemie), Forschungszentrum Jülich, D-52425 Jülich, Germany.
| |
Collapse
|